# Envisagenics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/envisagenics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.envisagenics.com/
- Total disclosed funding: $27M
- Latest round: Series B (Jun 4, 2024)
- Investors on record: 11

## About

Founded in 2014 and based in New York, US, Envisagenics, Inc. operates as a developer of predictive analytics platforms that allow scientists to translate basic discoveries into therapies. Maria Luisa Pineda (CEO) and Martin Akerman (CTO) are the co-founders of the company. In June 2024, Envisagenics, Inc. raised USD 25 million in Series B funding from Bristol-Myers Squibb, Empire State Development, Third Kind Venture Capital, and Red Cell Partners. The series B funding values Envisagenics, Inc. at USD 142.99 million post-money.

The company’s pipeline includes the SpliceCore® platform, which specializes in the identification and validation of drug targets by leveraging RNA sequencing data. SpliceCore® enhances the discovery of novel splicing-derived targets and elucidates the mechanisms of antisense drug regulation. In addition, SpliceIOTM, a branch of SpliceCore®, focuses on identifying tumor-specific neoepitopes for immunotherapy.

The organization plans to use the June 2024 funding to accelerate product development efforts and enhance business offerings.

## Funding rounds

- Series B, Jun 4, 2024, $25M — Empire State Development, Bristol-Myers Squibb, Third Kind Venture Capital, Red Cell Partners
- Series A, Sep 29, 2021 — Madrona Venture Group, M12, New York Ventures, Third Kind Venture Capital, Dynamk Capital, Red Cell Partners
- Seed, Nov 27, 2017, $2.4M — SV Angel, Dolby Family Ventures, New York Ventures, Third Kind Venture Capital, Dynamk Capital, The Cosine Group

## Investors

- SV Angel (https://capitalatlas.ai/funds/sv-angel) — Seed
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Seed
- New York Ventures (https://capitalatlas.ai/funds/new-york-ventures) — Seed, Series A
- Third Kind Venture Capital (https://capitalatlas.ai/funds/third-kind-venture-capital) — Seed, Series A, Series B
- Dynamk Capital (https://capitalatlas.ai/funds/dynamk-capital) — Seed, Series A
- The Cosine Group — Seed
- Madrona Venture Group (https://capitalatlas.ai/funds/madrona-venture-group) — Series A
- M12 (https://capitalatlas.ai/funds/m12) — Series A
- Red Cell Partners (https://capitalatlas.ai/funds/red-cell-partners) — Series A, Series B
- Empire State Development — Series B
- Bristol-Myers Squibb — Series B